PineTree Therapeutics, a Cambridge, MA-based biotech company which specializes in therapies in oncology, immuno-oncology and other diseases, raised $23.5M in Series A1 funding.
Backers included InterVest, SK Securities, DSC Investment, J Curve Investment, Samho Green Investment, and SJ Investment Partners.
The company intends to use the funds to advance their oncology and viral diseases platforms.
Led by CEO HoJuhn Song, PineTree Therapeutics is a pre-clinical stage biotech company that has developed the TAER-TAB™ and ViTRAP™ technologies and is building a broad pipeline for hard-to-treat cancers and viral diseases, with an initial focus on oncology.
FinSMEs
08/07/2022